Rectal Cancer Clinical Trial
Official title:
Organ-preserving Management in Patients With Complete or Near-complete Tumour Response After Preoperative Radio(Chemo)Therapy for Rectal Cancer
Watch-and-wait strategy in rectal cancer is gaining momentum. There is a large variability in
reporting the proportion of patients achieving clinical complete response (cCR) after
routinely delivered preoperative radio(chemo)therapy, likely because of patients' selection.
This proportion in population-based level is poorly defined. In addition, predictive factors
for cCR are also poorly defined. It is known that cCR response is observed often in small
tumours. However, cCR proportion in large cancers has not been sufficiently evaluated. For
example, even though pathological complete response (pCR) does occur in large fixed cancer,
it is unknown whether cCR does also occur because persistent fibrous stroma may mimic
residual cancer in all of such cases.
This is a prospective observational population-based cohort study on low rectal cancer to
answer the question of how often clinical or near-clinical tumour response occur after
routinely delivered preoperative radiotherapy in relation to the pre-treatment tumour
characteristics. The additional question was how often pCR occur in relation to the
pre-treatment tumour characteristics in the patients managed by total mesorectal excision
because of persistent tumour after radiotherapy. The additional aim was the implementation of
watch-and-wait strategy or full-thickness local excision (as an option instead of total
mesorectal excision in the patients with sustained near-cCR) within a frame of a prospective
study. In the patients managed by organ preservation, the secondary outcome measures were: i)
local regrowth rate, ii) effectiveness of salvage surgery, iii) disease-free survival at 3
years and overall survival at 5 years, iv) anorectal function.
Status | Recruiting |
Enrollment | 215 |
Est. completion date | January 1, 2026 |
Est. primary completion date | January 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Primary rectal cancer - Low tumour (accessible by digital rectal examination) - Routine preoperative radio(chemo)therapy according to the institutional policy; short-course radiation and immediate surgery is not allowed. - Informed consent for watch-and-wait strategy or local excision in patients with cCR and near-cCR Exclusion Criteria: - Recurrent cancer - Cancers situated in the upper rectum - Distant metastases |
Country | Name | City | State |
---|---|---|---|
Poland | Collegium Medicum Nicolaus Copernicus University and Oncology Centre | Bydgoszcz | |
Poland | Regional Oncological Centre | Kielce | |
Poland | Jagiellonian Medical University College | Kraków | |
Poland | St. John's Cancer Center | Lublin | |
Poland | Maria Sklodowska-Curie Institute - Oncology Center | Warsaw | Mazovian |
Poland | Silesian Oncological Centre | Wroclaw | |
Poland | NU-MED Centre for Cancer Diagnosis and Treatment | Zamosc |
Lead Sponsor | Collaborator |
---|---|
Maria Sklodowska-Curie Institute - Oncology Center | Polish Society of Surgical Oncology |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentages of cCR and near-cCR in the patients with "resectable" cancer | 11 weeks from the start of radiotherapy | ||
Primary | Percentages of cCR and near-cCR in the patients with threatened mesorectal fascia. | 11 weeks from the start of radiotherapy | ||
Primary | Percentages of cCR and near-cCR in relation to the selected tumour characteristics. | The selected tumour characteristics: TN categories, tumour length, degree of circumferential involvement, tumour mobility on digital rectal examination (mobile, tethered, fixed) and status of mesorectal fascia (threatened or not). | 11 weeks from the start of radiotherapy | |
Primary | Percentages of pCR in the patients after total mesorectal excision performed because of tumour persistence. | 12 weeks from the start of radiotherapy | ||
Secondary | Local regrowth rate | 5 years | ||
Secondary | Disease-free survival | 3 years | ||
Secondary | Overall survival | 5 years | ||
Secondary | Anorectal function assessed by low anterior resection syndrome (LARS) score | The questionnaire will be completed by patients. It includes 5 items related to anorectal function. The range of the score (0-42) is divided into 0 to 20 (no LARS), 21 to 29 (minor LARS) and 30 to 42 (major LARS). | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 |